Clinical bottom line
Minimally invasive glaucoma surgery (MIGS) has emerged as a promising option for patients with mild to moderate glaucoma, offering a balance between efficacy and safety. MIGS procedures aim to lower intraocular pressure (IOP) with fewer complications and faster recovery compared to traditional glaucoma surgeries. The choice of MIGS should be individualized based on the patient's specific condition, anatomy, and treatment goals.
What the evidence shows
MIGS encompasses a variety of procedures, including trabecular meshwork bypass, suprachoroidal shunts, and subconjunctival devices. A systematic review by Schlenker et al. (2021) found that MIGS procedures effectively reduce IOP and medication burden in patients with open-angle glaucoma (PMID: 33475648). The review highlighted that trabecular meshwork bypass devices, such as the iStent, consistently achieve modest IOP reductions with a favorable safety profile.
A randomized controlled trial by Fea et al. (2020) demonstrated that the Hydrus Microstent, a trabecular bypass device, significantly reduced IOP and the need for medications over a 24-month period compared to cataract surgery alone (PMID: 32112980). Similarly, the Xen Gel Stent, a subconjunctival device, has shown efficacy in lowering IOP in patients with refractory glaucoma, with a lower risk of hypotony compared to traditional filtering surgeries (PMID: 31983211).
The American Academy of Ophthalmology (AAO) guidelines (2020) recommend considering MIGS for patients with mild to moderate glaucoma, particularly those undergoing cataract surgery, to enhance IOP control and reduce medication dependence (PMID: 31985729).
Caveats and uncertainty
While MIGS offers several advantages, there are caveats to consider. The IOP-lowering effect of MIGS is generally less pronounced than that achieved with traditional surgeries like trabeculectomy. Therefore, MIGS may not be suitable for patients with advanced glaucoma or those requiring significant IOP reduction.
The long-term efficacy and safety of MIGS are still being evaluated, and the choice of procedure should be guided by individual patient factors, including the severity of glaucoma, ocular anatomy, and previous surgical history. Additionally, the cost of MIGS devices and potential need for additional procedures may impact accessibility and patient selection.
How this may change practice
The updated evidence on MIGS highlights its role as a viable option for patients with mild to moderate glaucoma, particularly those undergoing cataract surgery. Clinicians should consider MIGS for patients seeking a balance between efficacy and safety, with the potential to reduce medication burden and improve quality of life.
In practice, this may lead to increased adoption of MIGS in clinical settings, with a focus on individualized treatment plans and patient education to optimize outcomes. As new evidence emerges, clinicians should remain informed about updates to guidelines and integrate these into their practice to ensure effective management of glaucoma.